AstraZeneca's oral anti-obesity drug, elecoglipron, has shown promising results in a study, demonstrating a good safety and tolerability profile while leading to significant weight loss and appetite reduction.
AstraZeneca's oral anti-obesity pill, elecoglipron, shows promising results in a study, demonstrating a good safety and tolerance profile while inducing significant weight loss and appetite reduction.
Australia's One Nation party faces scrutiny over 'sloppy' financial reports with over $1m in missing assets. US President Trump accuses Iran of 'playing us for suckers' amid imminent strike threats. Thousands of Australian women face medicine uncertainty, while World Cup predictions begin.
AstraZeneca CEO Pascal Soriot discusses how AI enhances productivity in drug discovery and development, enabling smarter design, side effect reduction, and improved trial success prediction.
AstraZeneca hat für sein neues Blutdruckmedikament Baxfendy die Zulassung der US-Arzneimittelbehörde FDA erhalten. Das Mittel zielt auf Patienten, deren Blutdruck mit bestehenden Therapien nicht ausreichend kontrolliert werden kann, und soll einen Jahresumsatz von über 5 Milliarden Dollar generieren.
AstraZeneca's experimental breast cancer drug camizestrant faced a setback as a U.S. FDA advisory panel voted 6-3 against approval, citing concerns over the SERENA-6 trial design. The Phase 3 trial showed a 56% reduction in disease progression or death, but panel members weren't convinced early switching improved long-term survival. Shares fell 2% in morning trading, though analysts noted the drug's efficacy wasn't dismissed and the issue shouldn't impact AstraZeneca's $80 billion 2030 sales goal.
Oil and gas prices surge as reports indicate the US may extend its blockade of Iranian ports for months. Brent crude rose 5% to almost $117 a barrel, approaching the highest level since the Iran war began. UK gas prices also increased 5%, while the FTSE 100 fell 1.2% to its lowest level since April 1. President Trump met with energy company executives to discuss measures to calm oil markets amid the prolonged blockade.
AstraZeneca will invest £300m in the UK, completing its Cambridge headquarters and building a digital research facility in Macclesfield. The announcement marks a U-turn after the pharma giant paused £650m in projects last year due to disillusionment with the NHS business environment. Prime Minister Keir Starmer hailed the investment as a 'major vote of confidence' in the UK economy.
AstraZeneca is investing £300m in UK operations, Prime Minister Keir Starmer announced at PMQs, protecting jobs in Cambridge and Macclesfield. The investment comes seven months after the company paused a £200m Cambridge expansion and is tied to a new US pharmaceutical deal requiring UK to pay 25% more for medicines by 2035. Meanwhile, NIESR warns the Iran war could cost the UK £35bn in GDP over 2026-2027.
Türkiye’de prostat ve meme kanseri başta olmak üzere kritik hastalıkların tedavisinde kullanılan "Zoladex" isimli ilacın satışı, üretici firma AstraZeneca tarafından durduruldu. Muadili bulunmayan ilaca erişemeyen yaklaşık 30 bin hasta, tedavilerinin aksaması nedeniyle hayati tehlikeyle karşı karşıya.
AstraZeneca and GSK, the UK's second and ninth most valuable companies, both beat first-quarter profit expectations. AstraZeneca reported EPS of $2.58 versus $2.53 expected, while GSK posted EPS of £0.47 versus £0.43 expected. However, pharma CEOs including Novartis's Vas Narasimhan warned that Trump's MFN drug pricing policy could lead to fewer new drugs being launched in Europe unless continental competitiveness issues are addressed. AstraZeneca raised its 2026 guidance and is on track for its $80 billion revenue target by 2030.
